Antisense oligonucleotides to the epidermal growth factor receptor

Lois Witters, Rakesh Kumar, Mahitosh Mandal, C. Frank Bennett, Loren Miraglia, Allan Lipton

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Overexpression of the epidermal growth factor receptor (EGFR) has been observed in human breast tumors and is associated with poor prognosis in breast cancer patients. This would suggest that blocking the activity of the EGFR is a logical approach in the treatment of breast cancer. Three 20-mer phosphorothioate oligodeoxynucleotides were designed to target different regions of the human epidermal growth factor receptor (EGFR) mRNA. Several analogs of these oligodeoxynucleotides (the 2'-fluoro analog, the 2'-propoxy analog, and/or the 5-methyl cytosine analog) were also evaluated. We added these compounds to a human ovarian carcinoma cell line (SKOV3) and a human lung carcinoma line (A549), both of which overexpress the EGFR. All of these antisense oligonucleotides inhibited expression of the 10 kb EGFR mRNA (range: 22-97% inhibition) compared to a scrambled control oligonucleotide or an untreated control. Expression of the less prominent 5.6 kb EGFR mRNA band was also inhibited by all but two of the parent oligonucleotides. No inhibition of this 5.6 kb band was found with the control oligonucleotide. The reduction in the expression of EGFR mRNA by the three most potent antisense compounds was accompanied by a significant reduction of EGFR protein (90-98%) and in vitro growth inhibition of SKOV3 cells as compared to the control oligonucleotide.

Original languageEnglish (US)
Pages (from-to)41-50
Number of pages10
JournalBreast Cancer Research and Treatment
Volume53
Issue number1
DOIs
StatePublished - Mar 22 1999

Fingerprint

Antisense Oligonucleotides
Epidermal Growth Factor Receptor
Oligonucleotides
Messenger RNA
Oligodeoxyribonucleotides
Breast Neoplasms
Carcinoma
Cytosine
Cell Line
Lung
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Witters, Lois ; Kumar, Rakesh ; Mandal, Mahitosh ; Bennett, C. Frank ; Miraglia, Loren ; Lipton, Allan. / Antisense oligonucleotides to the epidermal growth factor receptor. In: Breast Cancer Research and Treatment. 1999 ; Vol. 53, No. 1. pp. 41-50.
@article{696e1a68b38a4c6cafce0841451a473b,
title = "Antisense oligonucleotides to the epidermal growth factor receptor",
abstract = "Overexpression of the epidermal growth factor receptor (EGFR) has been observed in human breast tumors and is associated with poor prognosis in breast cancer patients. This would suggest that blocking the activity of the EGFR is a logical approach in the treatment of breast cancer. Three 20-mer phosphorothioate oligodeoxynucleotides were designed to target different regions of the human epidermal growth factor receptor (EGFR) mRNA. Several analogs of these oligodeoxynucleotides (the 2'-fluoro analog, the 2'-propoxy analog, and/or the 5-methyl cytosine analog) were also evaluated. We added these compounds to a human ovarian carcinoma cell line (SKOV3) and a human lung carcinoma line (A549), both of which overexpress the EGFR. All of these antisense oligonucleotides inhibited expression of the 10 kb EGFR mRNA (range: 22-97{\%} inhibition) compared to a scrambled control oligonucleotide or an untreated control. Expression of the less prominent 5.6 kb EGFR mRNA band was also inhibited by all but two of the parent oligonucleotides. No inhibition of this 5.6 kb band was found with the control oligonucleotide. The reduction in the expression of EGFR mRNA by the three most potent antisense compounds was accompanied by a significant reduction of EGFR protein (90-98{\%}) and in vitro growth inhibition of SKOV3 cells as compared to the control oligonucleotide.",
author = "Lois Witters and Rakesh Kumar and Mahitosh Mandal and Bennett, {C. Frank} and Loren Miraglia and Allan Lipton",
year = "1999",
month = "3",
day = "22",
doi = "10.1023/A:1006127527107",
language = "English (US)",
volume = "53",
pages = "41--50",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

Antisense oligonucleotides to the epidermal growth factor receptor. / Witters, Lois; Kumar, Rakesh; Mandal, Mahitosh; Bennett, C. Frank; Miraglia, Loren; Lipton, Allan.

In: Breast Cancer Research and Treatment, Vol. 53, No. 1, 22.03.1999, p. 41-50.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antisense oligonucleotides to the epidermal growth factor receptor

AU - Witters, Lois

AU - Kumar, Rakesh

AU - Mandal, Mahitosh

AU - Bennett, C. Frank

AU - Miraglia, Loren

AU - Lipton, Allan

PY - 1999/3/22

Y1 - 1999/3/22

N2 - Overexpression of the epidermal growth factor receptor (EGFR) has been observed in human breast tumors and is associated with poor prognosis in breast cancer patients. This would suggest that blocking the activity of the EGFR is a logical approach in the treatment of breast cancer. Three 20-mer phosphorothioate oligodeoxynucleotides were designed to target different regions of the human epidermal growth factor receptor (EGFR) mRNA. Several analogs of these oligodeoxynucleotides (the 2'-fluoro analog, the 2'-propoxy analog, and/or the 5-methyl cytosine analog) were also evaluated. We added these compounds to a human ovarian carcinoma cell line (SKOV3) and a human lung carcinoma line (A549), both of which overexpress the EGFR. All of these antisense oligonucleotides inhibited expression of the 10 kb EGFR mRNA (range: 22-97% inhibition) compared to a scrambled control oligonucleotide or an untreated control. Expression of the less prominent 5.6 kb EGFR mRNA band was also inhibited by all but two of the parent oligonucleotides. No inhibition of this 5.6 kb band was found with the control oligonucleotide. The reduction in the expression of EGFR mRNA by the three most potent antisense compounds was accompanied by a significant reduction of EGFR protein (90-98%) and in vitro growth inhibition of SKOV3 cells as compared to the control oligonucleotide.

AB - Overexpression of the epidermal growth factor receptor (EGFR) has been observed in human breast tumors and is associated with poor prognosis in breast cancer patients. This would suggest that blocking the activity of the EGFR is a logical approach in the treatment of breast cancer. Three 20-mer phosphorothioate oligodeoxynucleotides were designed to target different regions of the human epidermal growth factor receptor (EGFR) mRNA. Several analogs of these oligodeoxynucleotides (the 2'-fluoro analog, the 2'-propoxy analog, and/or the 5-methyl cytosine analog) were also evaluated. We added these compounds to a human ovarian carcinoma cell line (SKOV3) and a human lung carcinoma line (A549), both of which overexpress the EGFR. All of these antisense oligonucleotides inhibited expression of the 10 kb EGFR mRNA (range: 22-97% inhibition) compared to a scrambled control oligonucleotide or an untreated control. Expression of the less prominent 5.6 kb EGFR mRNA band was also inhibited by all but two of the parent oligonucleotides. No inhibition of this 5.6 kb band was found with the control oligonucleotide. The reduction in the expression of EGFR mRNA by the three most potent antisense compounds was accompanied by a significant reduction of EGFR protein (90-98%) and in vitro growth inhibition of SKOV3 cells as compared to the control oligonucleotide.

UR - http://www.scopus.com/inward/record.url?scp=0033015612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033015612&partnerID=8YFLogxK

U2 - 10.1023/A:1006127527107

DO - 10.1023/A:1006127527107

M3 - Article

C2 - 10206071

AN - SCOPUS:0033015612

VL - 53

SP - 41

EP - 50

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -